Allogeneic B7-H3-targeted CAR-Vδ1T cell therapy in advanced solid tumors: A phase I study
This study provides clinical proof-of-concept for allogeneic B7-H3-targeted CAR-Vδ1T cells as a safe platform with low risk of GvHD and demonstrable biological activity in solid tumors. However, clinical efficacy was constrained by limited cellular persistence caused by host immune rejection. Future strategies are required to enhance the durability and therapeutic potential of this allogeneic approach.
Authors
- Min Tao (ORCID: https://orcid.org/0000-0002-7221-6084)
- J. Li (ORCID: https://orcid.org/0009-0006-0513-0383)
- T. Wang
- Changli Liu (ORCID: https://orcid.org/0000-0002-4531-5749)
- Jiajia Yuan
- Licui Jiang (ORCID: https://orcid.org/0009-0004-5996-7117)
- Yanshuo Cao (ORCID: https://orcid.org/0000-0003-4030-8600)
- H. Meng
- Z. Wang (ORCID: https://orcid.org/0000-0001-8307-693X)
- Min Wang (ORCID: https://orcid.org/0009-0003-0049-4557)
- Mengya Zhang (ORCID: https://orcid.org/0000-0002-1055-3528)
- J. Gong
- L. Shen
- Lin Yang
- Jian Li
- Yakun Wang
- Jun Zhou
- Changsong Qi
- Lian Liu
- Ran Xue
- Zhi Peng
- Zhihao Lu
- Siyuan Cheng
- Panpan Zhang
- Ting Xu
- Xiaotian Zhang
- Dan Liu
- Ming Lu
Institutions
- King University (US)
- Peking University (CN)
- Peking University Cancer Hospital (CN)
- PersonGen (China) (CN)
- Pro Persona (NL)
Publication Details
- Journal
- Clinical Cancer Research
- Published
- 2026-03-04
- DOI
- https://doi.org/10.1158/1078-0432.ccr-25-4600
- Primary Topic
- CAR-T cell therapy research
- Type
- article
- Field-Weighted Citation Impact
- 0.00